Know Cancer

or
forgot password

Phase II Study of RAD001 Plus Octreotide Depot in Patients With Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma (Carcinoid, Islet Cell)


Phase 2
18 Years
N/A
Not Enrolling
Both
Neuroendocrine Carcinoma, Islet Cell Carcinoma

Thank you

Trial Information

Phase II Study of RAD001 Plus Octreotide Depot in Patients With Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma (Carcinoid, Islet Cell)


RAD001 is a new drug that is designed to block a protein that is important in the growth of
cancer cells. Octreotide Depot is FDA approved for the treatment of carcinoid syndrome and
hormonal symptoms from certain islet cell carcinomas. Octreotide Depot may also help to
block certain proteins that are important in tumor growth.

Before you can start treatment on the study, you will have what are called "screening
tests". These tests will help the doctor decide if you are eligible to take part in the
study. You will be asked questions about your medical history and about any medications you
are currently taking or have taken in the past. You will have a complete physical exam and
your heart rate, temperature, breathing rate, blood pressure, height, and weight will be
measured. You will be asked about your ability to perform every day activities. Blood
(about 2 teaspoons) will be collected for routine tests. You will have an electrocardiogram
(ECG - a test that measures the electrical activity of the heart) and scans (either Computed
Tomography/CT or Magnetic Resonance Imaging/MRI) to evaluate the cancer. Women who are able
to have children must have a negative blood pregnancy test.

If the screening evaluations show you are eligible to take part in the study, you may begin
treatment. You will take RAD001 by mouth once a day, every day while on study. You should
take it in a fasting state or after no more than a light, fat-free meal. You should take
RAD001 about the same time each day. Octreotide Depot will be given as an injection into
the muscle of either buttock once every 4 weeks while on study. This will be done at M. D.
Anderson. Four weeks (28 days) is called one course of treatment.

Clinic visits will occur every 2 weeks during the first 4 weeks and every 4 weeks from then
on. At each clinic visit, you will be asked questions about your medical history and about
any medications you are currently taking or have taken in the past. You will have a
complete physical exam and your heart rate, temperature, breathing rate, blood pressure,
height, and weight will be measured. You will be asked about your ability to perform every
day activities. Blood samples (about 1 teaspoons) for routine tests will be collected every
2 weeks for the first 8 weeks. After that, blood samples (about 2 teaspoons) will be
collected every 4 weeks. CT or MRI scan(s) will be performed every 12 weeks.

If a sample of your tumor tissue that was removed previously is available, it will be
analyzed for expression of proteins that may effect tumor growth. However, if a sample is
not available, you will not be asked to undergo a biopsy to collect this tissue. This sample
may analyzed at any time during the study.

If you experience severe side effects, treatment may be delayed, stopped, or you may receive
smaller doses of RAD001 and/or Octreotide Depot. You may continue to receive up to at least
12 courses of study treatment unless the disease gets worse, you decide not to take part any
longer, or your doctor decides it is in your best interest to stop treatment. It may be
possible to continue treatment beyond 12 courses if you are benefitting from this treatment.

When you stop study treatment, you will be asked to have some tests and evaluations done.
About 4 teaspoons of blood will be taken for routine lab tests, You will also have a
physical exam and CT scan or MRI scan will be done to check the size and location of your
disease.

This is an investigational study. RAD001 is investigational and is not commercially
available. The drug combination in this study is also investigational. RAD001 is
manufactured by Novartis Pharmaceuticals Corporation. About 60 patients will take part in
this study. All will be enrolled at M. D. Anderson.


Inclusion Criteria:



- Patients with histologic proof of low grade neuroendocrine carcinoma will be
eligible. Both carcinoid (any site[atypical/intermediate grade carcinoid is allowed])
and islet cell (pancreatic endocrine tumor) will be eligible.

- Patients with neuroendocrine tumors associated with MEN1 syndrome will be eligible.

- Patients must have either metastatic or unresectable local-regional cancer.

- Patients must have measurable disease, as defined by RECIST (Response Evaluation
Criteria In Solid Tumors).

- Prior and concurrent octreotide (Sandostatin and Sandostatin LAR) is allowed.

- Prior radiation therapy is permitted. A recovery period of at least 4 weeks after
completion of radiotherapy is required prior to enrollment.

- Patients may have received 0, 1, or 2 prior cytotoxic chemotherapy.

- Chemotherapy used as a radiosensitizer will be considered one prior chemotherapy
regimen.

- Patients may have received prior interferon (not counted toward prior cytotoxic
chemotherapy).

- Patients may have received prior therapy targeting c-kit, abl, PDGFR (Platelet
Derived Growth Factor Receptor), VEGF (Vascular endothelial growth factor), or EGFR
[epidermal growth factor receptor] (not counted toward prior cytotoxic chemotherapy).

- Patients may have had prior hepatic artery embolization. There must be residual
measurable disease. Chemoembolization will be considered as one prior chemotherapy
regimen.

- Patients must have a performance status of 0, 1, or 2 (Zubrod scale).

- Patients must be >/= 18 years old (age limit due to lack of adequate safety data in
younger patients).

- Patients must give written informed consent.

- Patients should have adequate organ function defined as follows: Absolute
granulocytes > 1,500/mm3, hemoglobin > 8 g/dl, and platelets > 100,000/mm3. Serum
bilirubin < 1.5 x Upper Limit of Normal (ULN), serum creatinine < 1.5 mg/dL, AST
(SGOT) less/equal 2.5 x ULN, ALT (SGPT) less/equal 2.5 x ULN.

- Patients must have recovered from recent surgery. One week must have elapsed from the
time of a minor surgery and 4 weeks from major surgery.

- Fertile patients, both male and female, must practice contraception during treatment.

Exclusion Criteria:

- Patients may receive no other concurrent chemotherapy, immunotherapy, or
radiotherapy.

- Patients with intolerance to octreotide.

- Patients who have received chemotherapy, immunotherapy, or investigational therapy in
the 30 days prior to registration.

- Patients with uncontrolled diabetes mellitus as defined by fasting blood sugar > 1.5
x ULN.

- Pregnant or lactating women. All women of child-bearing potential must have a
negative pregnancy test prior to entry into the study. All patients of child-bearing
potential must be advised of the importance of avoiding pregnancy and using
appropriate methods of contraception while participating in this investigational
trial. Women who have had menses within the past 2 years, who have not had a tubal
ligation, or bilateral oophorectomy are considered to be of child-bearing potential.
Appropriate methods of contraception include hormonal or barrier method of birth
control; abstinence.

- Serious intercurrent infections, or nonmalignant medical illnesses that are
uncontrolled or whose control may be jeopardized by the complications of this
therapy.

- Psychiatric disorders rendering them incapable of complying with the requirements of
the protocol.

- Osseous metastasis as only site of disease.

- Any concurrent active malignancy other than non-melanoma skin cancers or
carcinoma-in-situ of the cervix. Patients with previous malignancies but without
evidence of disease for > 5 years will be allowed to enter the trial.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression Free Survival (PFS)

Outcome Description:

PFS is measured from date of trial entry until documented progression of disease or death from any cause. PFS is measured by computed tomography (CT) scans or magnetic resonance imaging (MRI) performed at baseline and after every three cycles.

Outcome Time Frame:

PFS assessed every 12 weeks (at the end of every 3 cycles) or more frequently if clinically indicated

Safety Issue:

No

Principal Investigator

James Yao, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

M.D. Anderson Cancer Center

Authority:

United States: Food and Drug Administration

Study ID:

2004-0597

NCT ID:

NCT00113360

Start Date:

January 2005

Completion Date:

July 2009

Related Keywords:

  • Neuroendocrine Carcinoma
  • Islet Cell Carcinoma
  • Neuroendocrine Carcinoma
  • Low Grade Neuroendocrine Carcinoma
  • Neuroendocrine Carcinoid
  • Islet Cell Carcinoma
  • RAD001
  • Everolimus
  • Octreotide Depot
  • Sandostatin LAR
  • Octreotide long-acting release (LAR)
  • Octreotide LAR
  • Carcinoma
  • Carcinoma, Neuroendocrine
  • Carcinoma, Islet Cell

Name

Location

UT MD Anderson Cancer CenterHouston, Texas  77030